ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB: MIVT) (FWB: MIV), a leading developer of next-generation biocompatible polymer-free drug-eluting stents and advanced drug delivery systems, announced that it has entered into a formal agreement to acquire Biosync Scientific, an India-based designer and developer of innovative interventional cardiology products, including cardiovascular stents.
